Autoimmune pancreatitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Iqra Qamar (talk | contribs) |
Iqra Qamar (talk | contribs) |
||
Line 24: | Line 24: | ||
====== Monitoring of clinical parameters in patients on glucocorticoid therapy: ====== | ====== Monitoring of clinical parameters in patients on glucocorticoid therapy: ====== | ||
* Glucocorticoids are tapered depending upon following clinical parameters: | * Glucocorticoids are tapered depending upon following clinical parameters:<ref name="pmid17525092">{{cite journal |vauthors=Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M |title=Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment |journal=Gut |volume=56 |issue=12 |pages=1719–24 |year=2007 |pmid=17525092 |pmc=2095691 |doi=10.1136/gut.2006.115246 |url=}}</ref><ref name="pmid18583399">{{cite journal |vauthors=Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, Seo DW, Lee SK |title=Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study |journal=Gut |volume=57 |issue=12 |pages=1704–12 |year=2008 |pmid=18583399 |doi=10.1136/gut.2008.150979 |url=}}</ref><ref name="pmid20736934">{{cite journal |vauthors=Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, Sauvanet A, Hentic O, Lévy P, Ruszniewski P, Hammel P |title=Outcome of patients with type 1 or 2 autoimmune pancreatitis |journal=Am. J. Gastroenterol. |volume=106 |issue=1 |pages=151–6 |year=2011 |pmid=20736934 |doi=10.1038/ajg.2010.314 |url=}}</ref><ref name="pmid19017924">{{cite journal |vauthors=Sahani DV, Sainani NI, Deshpande V, Shaikh MS, Frinkelberg DL, Fernandez-del Castillo C |title=Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy |journal=Radiology |volume=250 |issue=1 |pages=118–29 |year=2009 |pmid=19017924 |doi=10.1148/radiol.2493080279 |url=}}</ref> | ||
** Relief of symptoms | ** Relief of symptoms | ||
** Serial changes in abdominal imaging of the pancreas and bile ducts | ** Serial changes in abdominal imaging of the pancreas and bile ducts |
Revision as of 21:16, 2 January 2018
Autoimmune pancreatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Autoimmune pancreatitis medical therapy On the Web |
American Roentgen Ray Society Images of Autoimmune pancreatitis medical therapy |
Risk calculators and risk factors for Autoimmune pancreatitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]
Overview
Medical Therapy
Glucocorticoids:
- Preferred regimen : Prednisone is usually administered at an initial dose of 40 mg/d for 4 weeks followed by a taper of the daily dosage by 5 mg/wk depending upon the clinical parameters.
- Glucocorticoids are found to play an important role in the management of autoimmune pancreatitis via several ways such as:[1][2][3][4]
- Efficacy in alleviating symptoms
- Decreasing the size of the pancreas
- Reversing histopathologic features in patients with AIP
- Improvement of lab findings such as
- Resolution of hypergammaglobulinemia[5]
- Autoantibodies become undetectable
Response to Glucocorticoids:
- About 2/3rd of patients show good response to glucocorticoids with complete recovery.[6][7][8]
- Approximately 25% may require a second course of glucocorticoids.
- A few patients with autoimmune pancreatitis may require continuous treatment .
Monitoring of clinical parameters in patients on glucocorticoid therapy:
- Glucocorticoids are tapered depending upon following clinical parameters:[2][3][9][10]
- Relief of symptoms
- Serial changes in abdominal imaging of the pancreas and bile ducts
- Decreased serum γ-globulin and IgG4 levels
- Improvements in liver function tests
References
- ↑ Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N (2003). "Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma". Am. J. Gastroenterol. 98 (12): 2694–9. doi:10.1111/j.1572-0241.2003.08775.x. PMID 14687819.
- ↑ 2.0 2.1 Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M (2007). "Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment". Gut. 56 (12): 1719–24. doi:10.1136/gut.2006.115246. PMC 2095691. PMID 17525092.
- ↑ 3.0 3.1 Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, Seo DW, Lee SK (2008). "Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study". Gut. 57 (12): 1704–12. doi:10.1136/gut.2008.150979. PMID 18583399.
- ↑ Ito T, Nakano I, Koyanagi S, Miyahara T, Migita Y, Ogoshi K, Sakai H, Matsunaga S, Yasuda O, Sumii T, Nawata H (1997). "Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy". Dig. Dis. Sci. 42 (7): 1458–68. PMID 9246047.
- ↑ Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K (2001). "High serum IgG4 concentrations in patients with sclerosing pancreatitis". N. Engl. J. Med. 344 (10): 732–8. doi:10.1056/NEJM200103083441005. PMID 11236777.
- ↑ Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB (2008). "Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy". Gastroenterology. 134 (3): 706–15. doi:10.1053/j.gastro.2007.12.009. PMID 18222442.
- ↑ Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, Whitcomb DC, Slivka A (2009). "Evaluation and management of autoimmune pancreatitis: experience at a large US center". Am. J. Gastroenterol. 104 (9): 2295–306. doi:10.1038/ajg.2009.325. PMID 19532132.
- ↑ Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda MG, Novelli M, Winstanley A, Rodriguez-Justo M, Hatfield AR, Pereira SP, Webster GJ (2009). "Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis". Clin. Gastroenterol. Hepatol. 7 (10): 1089–96. doi:10.1016/j.cgh.2009.03.021. PMID 19345283.
- ↑ Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, Sauvanet A, Hentic O, Lévy P, Ruszniewski P, Hammel P (2011). "Outcome of patients with type 1 or 2 autoimmune pancreatitis". Am. J. Gastroenterol. 106 (1): 151–6. doi:10.1038/ajg.2010.314. PMID 20736934.
- ↑ Sahani DV, Sainani NI, Deshpande V, Shaikh MS, Frinkelberg DL, Fernandez-del Castillo C (2009). "Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy". Radiology. 250 (1): 118–29. doi:10.1148/radiol.2493080279. PMID 19017924.